Retatrutide
Retatrutide is an investigational "triple agonist" (GLP-1, GIP, and GCG receptor agonist) currently in Phase III trials, showing superior weight loss benefits compared to existing therapies. Studies indicate up to 24% body weight loss in 48 weeks, enhanced fat burning, significant reduction in liver fat, improved metabolic markers, and appetite
Key Guidelines:
Aseptic Technique: Clean vial stoppers and the injection site with alcohol pads.
Avoid Shaking: Vigorous shaking can damage the peptide structure.
Storage: Keep in the back of refrigerator, away from light.
Shelf Life: Reconstituted peptides are typically stable for 4–6 weeks in the refrigerator.
Dosage Tracking: Use an insulin syringe with U-100 markings to draw the correct dose.
Injection method: Subcutaneous (abdomen, thigh, or flank area)
For Research only
Key Benefits
Significant Weight Loss: Clinical trials showed that individuals lost up to 24.4% of their body weight within 48 weeks. Results showed 17% weight loss at 6 months.
Triple-Action Mechanism: Unlike semaglutide (GLP-1) or tirzepatide (GLP-1/GIP), retatrutide adds glucagon (GCG) receptor activation, which may increase energy expenditure and burn more fat, including fat around internal organs.
High Efficacy Rate: Data indicates 60-82% of patients achieved at least a 15% weight reduction.
Improved Metabolic Health: Beyond weight loss, it significantly improves hemoglobin A1c (HbA1c) levels, blood sugar, insulin sensitivity, and cholesterol levels.
Reduction in Liver Fat: Studies showed up to an 80% reduction in liver fat by week 24, making it a promising candidate for treating fatty liver disease.
Appetite and Cravings Control: Participants reported reduced appetite, leading to decreased snacking and lower caloric intake.
Potential for Enhanced Metabolic Function:By targeting GCG receptors, it helps maintain resting energy expenditure, potentially preserving more muscle while losing fat compared to traditional weight loss.
Clinical Side effects
Nausea: The most frequently reported symptom.
Diarrhea/Constipation: Common as the body adjusts.
Vomiting: Often linked to faster dosage increases.
Appetite Changes: Significant reduction in appetite.
Fatigue: A common, typically mild side effect.
Headaches/Dizziness: Often due to dehydration or rapid, reduced calorie intake.
Potential/Rare Side Effects
Increased Heart Rate: A slight increase in resting heart rate was observed in trials.
Skin Sensitivities: Some participants reported tingling or increased skin sensitivity.
Pancreatitis/Gallbladder Issues: While rare, these are potential risks associated with this class of medication.
Management and Considerations
"Start Low, Go Slow": Starting at 1 mg rather than 4 mg can reduce gastrointestinal side effects.
Duration: Side effects are strongest when initiating treatment or increasing the dose.
Hair Loss: Not specifically identified as a direct common effect of retatrutide, but is commonly associated with significant, rapid weight loss.
Medical journal Data
National library of medicine
https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
New England journal of medicine
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Oxford Online pharmacy
https://www.oxfordonlinepharmacy.co.uk/blog/what-is-retatrutide-triple-g
